Share on StockTwits
 

Research analysts at Argus raised their target price on shares of Actavis plc Ordinary Shares (NYSE:ACT) from $198.00 to $225.00 in a report released on Tuesday, American Banking & Market News reports. Argus’ price objective points to a potential upside of 1.18% from the company’s current price.

A number of other firms have also recently commented on ACT. Analysts at RBC Capital raised their price target on shares of Actavis plc Ordinary Shares from $240.00 to $249.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Barclays raised their price target on shares of Actavis plc Ordinary Shares from $230.00 to $250.00 in a research note on Wednesday, February 19th. They now have an “overweight” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Actavis plc Ordinary Shares from $202.00 to $237.00 in a research note on Wednesday, February 19th. They now have a “buy” rating on the stock. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $193.18.

Actavis plc Ordinary Shares (NYSE:ACT) opened at 222.37 on Tuesday. Actavis plc Ordinary Shares has a 52-week low of $83.19 and a 52-week high of $223.66. The stock’s 50-day moving average is $187.9 and its 200-day moving average is $159.1. The company’s market cap is $38.581 billion.

Actavis plc Ordinary Shares (NYSE:ACT) last posted its quarterly earnings results on Thursday, February 20th. The company reported $3.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $3.05 by $0.12. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.68 billion. Analysts expect that Actavis plc Ordinary Shares will post $12.98 EPS for the current fiscal year.

Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.